A group of investors advised by Munich-based Rigeto Unternehmerkapital has acquired prevention-center as an add-on to the Matignon Group. Prevention-center is a leading Swiss provider of cosmetic, medical and aesthetic services in the field of
Tags :Christian Schneiter
Fangda Carbon New Material Co., an integrated carbon materials producer in in the People’s Republic of China with diversified product offerings, including graphite electrodes, carbon blocks, isostatic graphite and iron ore concentrates, sold 22m
As we have informed here, the Helsinn Group has closed a financing agreement with Oberland Capital Management. In this sense, VISCHER has advised Oberland Capital Management on its financing agreement with the Ticino based group.
The German company E3 Holding has acquired the clean-tek group from Felix Ritter. Clean-tek, based in Germany and Basel, is a leading manufacturer of modern cleanroom systems that uses technology for sensitive areas such as
As we have informed last 15 November 2022 here, Hangzhou GreatStar Industrial, whose A Shares are listed on the Shenzhen Stock Exchange, became the eighth Chinese company that has listed global depositary receipts (GDRs) on the SIX
Norgine Ventures has provided financing of approx. EUR 10 million to Lunaphore Technologies, a privately owned Swiss company spun out from EPFL. The financing was realised in form of private bonds with warrants which can be
As we have informed last 28th July, Keda Industrial Group and Ningbo Shanshan were among the first companies which successfully listed global depositary receipts (
VISCHER has advised Macquarie Bank on Swiss law issues in connection with a new USD 40 million credit facility for Trident Royalties, the London-based mining royalty and streaming company. Mayer Brown was the bank’s international
Relief Therapeutics, a biopharmaceutical company, has launched a Level 1 American Depositary Receipt (“ADR”) program in the United States. From 18 November 2021, ADRs can be traded over-the-counter. Relief’s ADR program complements the existing main listing of
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from
